[2009] [SAT0241] RAYNAUD'S SYNDROME EVOLUTION IN SYSTEMIC SCLERODERMA PATIENTS ON DIFFERENT TREATMENT PATTERNS

S. Agachi, L. Groppa General Medicine, The State Medical and Pharmaceutical University Nicolae Testemitsanu, Kisinau, Moldova Republic

Objectives: to evaluate the different treatment patterns efficiency of Raynaud's syndrome in Systemic Scleroderma patients.
Methods: The study included 45 Systemic Scleroderma patients. All patients had limited type disease, chronic evolution, in a late phase. As diagnostic tools we have used ARA criteria (1980).Only female patients were included. The median age of patients were 38.7±2.3 years, with a median disease duration of 10.5±1.08 years. All patients were equally divided in 3 groups. Group 1 received pentoxiphylline 1200mg pd. Group 2, in addition to pentoxiphylline, received lisinopril 10mg pd Group 3, in addition to pentoxiphylline, received Eprosartan 600 mg pd. Every 6 months patients were evaluated. Clinical evaluation (duration and frequency of seizures, complications onset - erosions, necrosis) and quality of life assessment (SF 36) were performed.
Results: the length of seizures after six months of treatments decreased in group 1 from 25,2±3,8 minutes to 20,5±3,6 minutes; in group 2 from 23,4±3,1min to 15,4±2,1 min; and in group 3 from 24,9±2,9 min to 7,4±1,5 min (p<0,05). Seizure frequency after 6 months of treatment in group 1 was 26.7%, in group 6.7% and no seizures were assessed in group 3 (p<0,01). Quality of life assessment (SF 36) improved: in group 1 from 85,2±7,8 prior to treatment to 84,5±7,6 points; in group 2 from 86,3±7,6 points to 72,8±5,3 points and in group 3 from 84,5±6,7 points to 60,3±3,2 (p<0,05).
Conclusion: the 3 different treatment patterns showed positive results on Raynaud's syndrome evolution; also improving Systemic Scleroderma patients' quality of life. The best results, however, were obtained in patients receiving a combination of pentoxiphylline and Eprosartan. One explanation for that, could be in the additional influence of eprosartan on peripheral vessel resistance.
Disclosure of Interest: None declared

Ann Rheum Dis 2009;68(Suppl3):619

Scleroderma, myositis and related syndromes